Lewes, DE -- (SBWIRE) -- 09/07/2013 -- LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: Hologic, Inc. (NASDAQ:HOLX), ProShares Trust UltraPro Short QQQ ETF (NASDAQ:SQQQ), Viacom, Inc. (NASDAQ:VIAB), Celgene Corporation (NASDAQ:CELG).
Hologic, Inc.(NASDAQ:HOLX) ended higher +0.80% and complete the day at $21.39. The total number of shares changed hands during the day was 3.74 million. After opening at $21.24, the stock hit as high as $21.50. However, it traded between $18.45 and $23.96 over the last twelve months.
Hologic, Inc. develops, manufactures, and supplies diagnostics, medical imaging systems, and surgical products for women. The company’s Breast Health segment offers full field digital mammography, C-View, screen-film mammography, computer aided detection, Trident specimen radiography
For How Long HOLX will Fight for Profitability? Read This Trend Analysis report
ProShares Trust UltraPro Short QQQ ETF(NASDAQ:SQQQ) closed yesterday at $22.43, a -0.58% decrease. Around 3.32 million shares were traded, beating an-average trading volume of 2.28 million shares. The company is now valued at around $218.83 million.
The investment seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the NASDAQ-100 Index®. The fund invests in derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as three times the inverse (-3x) of the daily return of the index.
Has SQQQ Found The Bottom And Ready To Gain Momentum? Find Out Here
Viacom, Inc.(NASDAQ:VIAB) moved +0.48 percent higher at $80.29 and traded between $79.00 and $81.06 after opening the day at $80.53. Its performance over the last five days remained 1.08%, which stands at 1.83% for a month. Going back further than one month, 1-year performance after recent close was 52.24%.
Viacom Inc. operates as an entertainment content company in the United States and internationally. The company connects with audiences through compelling content on television, motion picture, online, and mobile platforms. It operates in two segments, Media Networks and Filmed Entertainment.
For How Long VIAB Gloss will Attract Investors? Find out via this report
Celgene Corporation(NASDAQ:CELG) shares rose, gaining +0.95 percent to close at $146.97. The stock is up around 87.29% this year and 104.01% for the last 12 months. Around 3.22million shares changed hands yesterday, higher from an-average trading volume of 2.33 million shares.
Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Its commercial stage products include REVLIMID, a drug to treat multiple myeloma and transfusion-dependent anemia; VIDAZA, a nucleoside analog to treat intermediate-2 and myelodysplastic syndromes (MDS), and acute myeloid leukemia.
Why Should Investors Buy CELG After The Recent Gain? Just Go Here and Find Out
About LeadingStockAlerts
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.
Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.
Disclaimer
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/